Douglas Drossman1, Eva Szigethy2. 1. Department of Medicine and Psychiatry, University of North Carolina Center for Functional GI and Motility Disorders, and Drossman Gastroenterology PLLC, Chapel Hill, North Carolina, USA. 2. 1] Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA [2] Division of Gastroenterology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
OBJECTIVES: The paradoxical development of chronic abdominal pain is an underrecognized side effect of opioid use. Narcotic bowel syndrome (NBS), occurring in a small proportion of chronic opioid users, consists of chronic or intermittent abdominal pain, which often increases in severity despite continued or escalating dosages of opioids prescribed to relieve pain. METHODS: A PubMed search was conducted using terms such as "narcotic bowel syndrome" and "opioid hyperalgesia" through January 2014. RESULTS: Abdominal pain is the defining symptom of NBS and is thought to be mediated by central nervous system dysfunction; it should be distinguished from the peripheral side effects of opioids, such as nausea, bloating, intermittent vomiting, abdominal distension, and constipation. This latter cluster of symptoms is called opioid bowel dysfunction, although it may co-occur with NBS. Hypothesized mechanisms of the central effects of opioids on nociception in NBS include spinal cord inflammation and dysfunction in opioid receptor activity and related neuroanatomical substrates. With continued use, ∼6% of patients taking narcotics chronically will develop NBS, with profound consequences in terms of daily function. The primary management paradigm for NBS is a structured opioid withdrawal program accompanied by centrally acting adjunctive therapy comprising antidepressants, benzodiazepines, and clonidine to target pain, anxiety, and depression, and prevent withdrawal effects, in addition to peripherally acting agents such as laxatives (e.g., osmotic laxatives and chloride channel activators) to control transient constipation. Such structured withdrawal programs have been prospectively evaluated in small clinical trials and have met with considerable success in the short term. CONCLUSIONS: Because rates of NBS are likely to rise, integrated intensive pharmacotherapy and psychosocial interventions are needed to help patients with NBS go off and stay off opioids. These programs will likely also reduce comorbid psychopathology and lead to adequate pain control and improved quality of life.
OBJECTIVES: The paradoxical development of chronic abdominal pain is an underrecognized side effect of opioid use. Narcotic bowel syndrome (NBS), occurring in a small proportion of chronic opioid users, consists of chronic or intermittent abdominal pain, which often increases in severity despite continued or escalating dosages of opioids prescribed to relieve pain. METHODS: A PubMed search was conducted using terms such as "narcotic bowel syndrome" and "opioid hyperalgesia" through January 2014. RESULTS:Abdominal pain is the defining symptom of NBS and is thought to be mediated by central nervous system dysfunction; it should be distinguished from the peripheral side effects of opioids, such as nausea, bloating, intermittent vomiting, abdominal distension, and constipation. This latter cluster of symptoms is called opioid bowel dysfunction, although it may co-occur with NBS. Hypothesized mechanisms of the central effects of opioids on nociception in NBS include spinal cord inflammation and dysfunction in opioid receptor activity and related neuroanatomical substrates. With continued use, ∼6% of patients taking narcotics chronically will develop NBS, with profound consequences in terms of daily function. The primary management paradigm for NBS is a structured opioid withdrawal program accompanied by centrally acting adjunctive therapy comprising antidepressants, benzodiazepines, and clonidine to target pain, anxiety, and depression, and prevent withdrawal effects, in addition to peripherally acting agents such as laxatives (e.g., osmotic laxatives and chloride channel activators) to control transient constipation. Such structured withdrawal programs have been prospectively evaluated in small clinical trials and have met with considerable success in the short term. CONCLUSIONS: Because rates of NBS are likely to rise, integrated intensive pharmacotherapy and psychosocial interventions are needed to help patients with NBS go off and stay off opioids. These programs will likely also reduce comorbid psychopathology and lead to adequate pain control and improved quality of life.
Authors: Ning Wu; Shih-Yin Chen; Lindsay A Hallett; Luke Boulanger; Kimberly A Fraser; Chintan K Patel; Yang Zhao Journal: Pain Pract Date: 2011 Jan-Feb Impact factor: 3.183
Authors: Guilherme R Souza; Jhimmy Talbot; Celina M Lotufo; Fernando Q Cunha; Thiago M Cunha; Sérgio H Ferreira Journal: Proc Natl Acad Sci U S A Date: 2013-06-17 Impact factor: 11.205
Authors: Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins Journal: Brain Behav Immun Date: 2009-08-11 Impact factor: 7.217
Authors: Rok Seon Choung; G Richard Locke; Alan R Zinsmeister; Cathy D Schleck; Nicholas J Talley Journal: Am J Gastroenterol Date: 2009-04-14 Impact factor: 10.864
Authors: Wenjun Zhu; Crystal Acosta; Brian MacNeil; Claudia Cortes; Howard Intrater; Yuewen Gong; Mike Namaka Journal: Biomed Res Int Date: 2013-09-24 Impact factor: 3.411
Authors: Henry P Parkman; Laura A Wilson; William L Hasler; Richard W McCallum; Irene Sarosiek; Kenneth L Koch; Thomas L Abell; Ron Schey; Braden Kuo; William J Snape; Linda Nguyen; Gianrico Farrugia; Mandhusudan Grover; John Clarke; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha Journal: Dig Dis Sci Date: 2019-03-09 Impact factor: 3.199